Mark Busgang appointed as illumiSonics Inc., President and CEO
Waterloo, Canada, July 24, 2019 -(illumisonics.com)- illumiSonics Inc., a developer of PARS™ Technology, is please to announce that Mark Busgang, the former COO of FCM Recycling Inc., will be joining as illumiSonics President and CEO effective August 1, 2019.
Concurrently with his mandate at FCM, Mr. Busgang was President of Busgang Consultants, focused on strategic planning and M&A. From 1998 to 2011 Mr. Busgang was Founder, President, and CEO of Warnex Ltd., a Laboratory Services company listed on the TSX. In 1993 Mark co-founded Theratechnologies Inc., a biotechnology company listed on the TSX, and served as Vice–President responsible for commercial operations. Prior to that, he served as President of Pharmetics Ltd, a leading Canadian contract manufacturer of pharmaceutical and nutraceutical products.
Mark has served on the boards of several private and public companies and institutions and charitable organizations. He was a finalist for the Ernst and Young Entrepreneur of the Year award in 2011 and is currently a member of YPO/WPO. He holds a B. Comm. degree in Accounting from Concordia University in Montreal and an MBA from the Martino School of Business at Fordham University in New York.
“We are excited to have Mr. Busgang join our team,” Parsin H. Reza, Founder and CTO at illumiSonics, notes. “His experience in leading and growing businesses during his career brings us a dynamic and knowledgeable executive as we move from the discovery phase to pre-clinical and commercialization.”
“I am looking forward to working with the illumiSonics team” said Busgang. IIllumisonics and its PARS™ technology represent a breakthrough in diagnostic imaging and an incredible opportunity to change the field of diagnostic and surgical microscopy.
About illumiSonics Inc.
illumiSonics Inc., develops, patents and commercialized PARS™ advanced optical imaging systems for a wide range of pre-clinical and clinical applications. Our proprietary PARS™ photoacoustic remote sensing technology is a revolution in optical imaging. Like traditional photoacoustic imaging, PARS™ measures optical absorption and is capable of providing functional and molecular imaging of anything that can absorb light. PARS™ is the first fully optical, non-contact photoacoustic imaging technology. This allows PARS™ to maintain all of the advantages of photoacoustic imaging while addressing its short comings which provides incredible flexibility in how it can be deployed. illumiSonics is a privately owned Canadian company. For more information visit http://www.illumisonics.com/ or email us at contact@illumisonics.com.
Concurrently with his mandate at FCM, Mr. Busgang was President of Busgang Consultants, focused on strategic planning and M&A. From 1998 to 2011 Mr. Busgang was Founder, President, and CEO of Warnex Ltd., a Laboratory Services company listed on the TSX. In 1993 Mark co-founded Theratechnologies Inc., a biotechnology company listed on the TSX, and served as Vice–President responsible for commercial operations. Prior to that, he served as President of Pharmetics Ltd, a leading Canadian contract manufacturer of pharmaceutical and nutraceutical products.
Mark has served on the boards of several private and public companies and institutions and charitable organizations. He was a finalist for the Ernst and Young Entrepreneur of the Year award in 2011 and is currently a member of YPO/WPO. He holds a B. Comm. degree in Accounting from Concordia University in Montreal and an MBA from the Martino School of Business at Fordham University in New York.
“We are excited to have Mr. Busgang join our team,” Parsin H. Reza, Founder and CTO at illumiSonics, notes. “His experience in leading and growing businesses during his career brings us a dynamic and knowledgeable executive as we move from the discovery phase to pre-clinical and commercialization.”
“I am looking forward to working with the illumiSonics team” said Busgang. IIllumisonics and its PARS™ technology represent a breakthrough in diagnostic imaging and an incredible opportunity to change the field of diagnostic and surgical microscopy.
About illumiSonics Inc.
illumiSonics Inc., develops, patents and commercialized PARS™ advanced optical imaging systems for a wide range of pre-clinical and clinical applications. Our proprietary PARS™ photoacoustic remote sensing technology is a revolution in optical imaging. Like traditional photoacoustic imaging, PARS™ measures optical absorption and is capable of providing functional and molecular imaging of anything that can absorb light. PARS™ is the first fully optical, non-contact photoacoustic imaging technology. This allows PARS™ to maintain all of the advantages of photoacoustic imaging while addressing its short comings which provides incredible flexibility in how it can be deployed. illumiSonics is a privately owned Canadian company. For more information visit http://www.illumisonics.com/ or email us at contact@illumisonics.com.